Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab + TCS in Japanese Pediatric Atopic Dermatitis
NCT04678882Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Dupilumab + TCS with Placebo + TCS (2 arms). Primary endpoint: Proportion of participants with >=75% improvement in Eczema Area and Severity Index at 16 weeks. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04678882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678882.